Fig. 7: Analysis of CXCL13 in serum in relation to immunization. | npj Vaccines

Fig. 7: Analysis of CXCL13 in serum in relation to immunization.

From: Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge

Fig. 7

a CXCL13 (log10 pg/mL) in pre-challenged serum. Two-way ANOVA with Sidak’s multiple comparisons test was performed for statistical analysis. P < 0.0001****. Naïve baseline represented as dotted line at 1.861183. b Post challenged CXCL13 levels in the serum. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was performed for statistical analysis. P = 0.0112*, P = 0.0018**, and P < 0.0001****. All results represented as mean ± SD.

Back to article page